GW Pharmaceuticals receives European Commission approval for EPIDYOLEX®

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex. Read the PDF document here.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

More To Explore